Background/Aim: To evaluate the effectiveness of enzalutamide in Italian patients with hormone-refractory metastatic castration-resistant prostate cancer, progressing after chemotherapy with docetaxel plus prednisone. Patients and Methods: A total of 60 patients were enrolled. Reduction in serum prostate-specific antigen (PSA) was assessed as the primary endpoint, while reduction in pain, safety, progression-free survival and overall survival represented secondary endpoints. Results: Enzalutamide was well tolerated, with a manageable toxicity profile and a modest objective response rate. A considerable difference in serum levels of PSA before and after treatment was observed. A significant correlation between PSA response and overall survival was also noted. The regression analysis revealed PSA level to be predictive of overall survival. Conclusion: Enzalutamide was shown to be an effective and welltolerated therapeutic option in patients with metastatic castration-resistant prostate cancer progressing after docetaxel plus prednisone treatment.

Cicero, G., DE LUCA, R., Dorangricchia, P., & Dieli, F. (2017). The clinical efficacy of enzalutamide in metastatic prostate cancer: Prospective single-center study. ANTICANCER RESEARCH, 37(3), 1475-1480 [10.21873/anticanres.11472].

The clinical efficacy of enzalutamide in metastatic prostate cancer: Prospective single-center study

CICERO, Giuseppe;DE LUCA, Rossella;DORANGRICCHIA, PATRIZIA;DIELI, Francesco
2017

Abstract

Background/Aim: To evaluate the effectiveness of enzalutamide in Italian patients with hormone-refractory metastatic castration-resistant prostate cancer, progressing after chemotherapy with docetaxel plus prednisone. Patients and Methods: A total of 60 patients were enrolled. Reduction in serum prostate-specific antigen (PSA) was assessed as the primary endpoint, while reduction in pain, safety, progression-free survival and overall survival represented secondary endpoints. Results: Enzalutamide was well tolerated, with a manageable toxicity profile and a modest objective response rate. A considerable difference in serum levels of PSA before and after treatment was observed. A significant correlation between PSA response and overall survival was also noted. The regression analysis revealed PSA level to be predictive of overall survival. Conclusion: Enzalutamide was shown to be an effective and welltolerated therapeutic option in patients with metastatic castration-resistant prostate cancer progressing after docetaxel plus prednisone treatment.
http://ar.iiarjournals.org/content/37/3/1475.full.pdf+html
Cicero, G., DE LUCA, R., Dorangricchia, P., & Dieli, F. (2017). The clinical efficacy of enzalutamide in metastatic prostate cancer: Prospective single-center study. ANTICANCER RESEARCH, 37(3), 1475-1480 [10.21873/anticanres.11472].
File in questo prodotto:
File Dimensione Formato  
Enzalutamide.pdf

non disponibili

Dimensione 141.44 kB
Formato Adobe PDF
141.44 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10447/244660
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 8
social impact